FDA Approves Sagent’s Generics of Imitrex, Zemuron

Sagent Pharmaceuticals Inc. Aug. 2 announced that the Food and Drug Administration has approved its generic versions of GlaxoSmithKline’s Imitrex (sumatriptan succinate injection) and Merck’s Zemuron (rocuronium bromide injection).

Imitrex is indicated for the treatment of migraines and Zumuron is indicated as an addition to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation, the Schaumburg, Ill.-based company said.

These generic drugs are the eighth and ninth products approved from Sagent’s partnership with Strides Arcolab. Under this venture, Sagent and Strides Arcolab jointly are developing, supplying, and ...